|
EXPERTISE
- 12+
years pharmaceutical regulatory experience.
- 7+
years regulatory chemistry, manufacturing and controls
(CMC) experience at CDER/FDA with focus on small molecular-weight
drugs. Complementary regulatory experience on CDER-regulated
biologics.
- 3+
years research experience at CBER/FDA.
- Regulatory
guidance and strategy from pre-IND through NDA/BLA approval.
- Primary
CMC review and assessment of drug product development
- Drug
substance and drug product analytical method development
and validation.
- Drug
substance and drug product stability protocol development
and stability data analysis.
- Gap
analysis of drug development strategy.
- Due
diligence audit of firm's product development data.
- Manufacturing
contractor and vendor evaluation and selection.
- Management
and technical oversight of contract manufacturing organizations
(CMOs).
- Unique
combination of biologic/biotechnological and small molecular-weight
drug regulatory experience.
- Experienced
in chemical synthesis, small-scale and pilot-scale fermentation,
biologics/biotechnology, and protein chemistry.
- Experienced
working in cross-functional teams (i.e., Pharmacology/toxicology,
Clinical,
Biostatistics, Biopharmaceutics, and Analytical).
- Ph.D.
in Organic Chemistry; M.B.A. degree and training for managers.
EDUCATION
| MBA |
|
Finance,
Robert H. Smith School of Business, University of
Maryland, College Park, MD (2002) |
| Ph.D. |
|
Organic
Chemistry, University of Maryland, College Park, MD
(1989) |
| B.A. |
|
Biochemistry,
University of Pennsylvania, Philadelphia, PA (1984) |
EXPERIENCE:
CURRENT
POSITION:
Jan. 2005 - Present |
|
Senior
Consultant, Biologics Consulting Group, Inc.
Potomac, MD
- Evaluate
client CMC scientific and regulatory strategies for
a wide range of therapeutic drug products (biologic
and non-biologic) at all stages of product development,
from pre-IND through post-NDA approval.
- Review
and provide advice on IND and NDA submissions for
suitability relative to FDA expectations for CMC data.
- Perform
gap analysis audits for deficiencies relative to FDA
expectations.
- Conduct
regulatory and scientific due diligence audits for
business acquisitions and licensing partnerships.
Provide assessment of strengths and deficiencies.
- Represent
clients in interactions with FDA.
- Represent
client as FDA regulatory expert in legal proceedings.
- Prepare
and write submissions to FDA, with focus on CMC sections.
- Provide
scientific and regulatory training and presentations
at pharmaceutical/biopharmaceutical conferences.
|
|
|
|
|
| July
2003 - Dec. 2004 |
|
Division
Director (acting) March 2004 - Dec. 2004, Deputy Division
Director (acting) July 2003 - March 2004. FDA, CDER,
Office Of New Drug Chemistry, Division Of New Drug Chemistry
III. Rockville, MD.
- Supervised
34 employees in 9 therapeutic product classes, includes
6 Team Leaders, review chemists and administrative
staff.
- Planned
and set long-range plans and schedules for Division
work. Directed and coordinated workload, and assured
implementation of Division policies, goals and objectives.
- Made
critical decisions and provided expert advice concerning
regulatory and scientific approaches and options consistent
with Office policies and objectives.
- Evaluated
budget and fiscal controls to manage Division functions.
- Evaluated
Team Leader and review chemist performance.
- Performed
tertiary reviews of NDAs for new molecular entities.
- Represented
FDA in dealing and negotiating with the regulated
industry, and professional and industry organizations.
- Participated
as invited speaker at regulatory and scientific conferences.
- Served
as the Chair of the Stability Guidance Technical Committee,
Co-chair of the Conjugated Estrogens Working Group
and CO-chair of the Good Review Practices Working
Group.
|
|
|
|
| Oct.
2001-July 2003 |
|
Lead
Chemist (Team Leader), FDA, CDER, Division Of Reproductive
and Urologic Drug Products. Rockville, MD.
- Managed
a team of 4 review chemists in 2 therapeutic product
classes.
- Responsible
for secondary review, consistency of CMC reviews and
adherence to FDA/ONDC policies and guidances.
- Coordinated
reviewers' workload of IND and NDA submissions to
ensure that reviews were conducted in timely manner.
- Extensive
interactions with the regulated industry to provide
regulatory direction during IND drug development and
NDA post-approval activities.
- Active
in the development of FDA guidances for industry and
internal good review practices. Served as the Chair
of the Stability Guidance Technical Committee, CO-chair
of the Conjugated Estrogens Working Group and CO-chair
of the Good Review Practices Working Group.
|
|
|
|
| Apr.
1997-Oct. 2001 |
|
Chemistry
Reviewer, FDA, CDER, Division Of Reproductive And
Urologic Drug Products. Rockville, MD.
- Evaluated
the quality of new drug products submitted to the
FDA for approval.
- Integral
part of a review team responsible for evaluating the
quality and effectiveness of reproductive and urologic
drug products being investigated in clinical studies.
- Major
contributor to committees responsible for establishing
drug product quality standards and publishing guidances
for pharmaceutical companies.
- Provided
regulatory guidance to pharmaceutical company representatives
during drug product development through direct face-to-face
meetings.
- Mentored
new reviewers.
- Served
as computer focal point to facilitate and troubleshoot
computer issues.
|
|
|
|
| Feb.
1994-Apr. 1997 |
|
National
Research Council Fellow, FDA, CBER, Laboratory of
Parasitic Biology and Biochemistry. Bethesda, MD
- Investigated
the biological role of specific proteins in the sexual
differentiation of the malaria parasite. Published
three research papers in peer-reviewed journals.
- Presented
research data at three separate scientific conferences.
- Supervised
the research projects of college students.
- Responsible
for the coordination of instrument repairs and the
ordering of laboratory supplies.
|
|
|
|
| July
1989-Jan. 1994 |
|
Staff
Scientist, General Electric Co., Corporate Research
& Development, Biological Sciences Laboratory. Schenectady,
NY.
-
Developed recombinant biphenyl-metabolizing microorganisms
capable of degrading environmental contaminants. Marketed
this technology to the GE business units and government
agencies responsible for environmental clean-up.
- Investigated
the factors affecting aerobic biodegradation of indigenous
PCBs in Hudson River sediment by various bacterial
strains.
- Isolated
and conducted mechanistic studies of the dioxygenase
enzymes involved in biodegradation.
- Investigated
the scientific and economic feasibility of biologically
synthesizing aromatic monomers for use as a feedstock
to produce biodegradable polymers.
- Supervised
research projects of summer interns.
- Published
research in peer-reviewed journals.
- Recruited
at major East Coast universities. Interviewed and
screened graduating science Ph.D. students for second
round interviews at the Research Center.
|
|
|
|
| May
1985-May 1989 |
|
Research
Assistant, University of Maryland, Dept. of Chemistry/Biochemistry.
College Park, MD.
- Investigated
mechanism of action of two bacterial enzymes, mandelate
racemase and D-amino acid oxidase.
- Synthesized
and tested novel halogenated aromatic hydroxy- and
amino- acid analogs as potential irreversible inhibitors.
- Published
research in peer-reviewed journals and co-authored
one chapter in a biotechnology book. In addition,
the research data was presented at two national scientific
conferences.
- Served
as the computer expert for the laboratory group.
|
HONORS
AND AWARDS (Selected Listing)
| May
2004 |
FDA's
Group Recognition Award |
| Nov
2002 |
CDER's
Special Recognition Award |
| Nov
2002 |
CDER's
Team Excellence Award |
ADDITIONAL
TRAINING (Selected Listing)
| Fall
2002 |
Facilitation
Skills, CDER |
| Feb.
2002 |
Group
Decision-Making Techniques, CDER |
| Spring
2002 |
Managing
Written Communications for Team Leaders, CDER |
| Fall
1999 |
Organizational
Behavior and Human Resources, University of Maryland |
PRESENTATIONS
(Selected Listing)
| Dec.
2005 |
|
IBC
Biopharm Manufacturing and Distribution Summit: Logistics
for Biopharmaceutics, "Stability Studies to Support
the Chain of Custody of Biotechnology Products,"
Reston, VA. |
| Nov.
2005 |
|
2005
AAPS Annual Meeting: AAPS Short Course on Degradation
and Stability in Small Molecule Active Pharmaceutical
Ingredients/Stability Testing for Global Filings, "Stability
Requirements for Global Regulatory Filings," Nashville,
TN. |
| Mar.
2005 |
|
International
Pharmaceutical Federation (FIP) Workshop: Harmonizing
Clinical Trial GMP and Quality Requirements Across the
EU and Beyond, "The US Investigational New Drug (IND)
System," Noordwijk Zee, The Netherlands. |
| Nov.
2004 |
|
2004 AAPS Annual Meeting, "Phase 2 and 3 IND CMC
Guidance: FDA
Perspective," Baltimore, MD |
| Sept.
2004 |
|
64th
Annual World International Pharmaceutical Federation (FIP)
Congress, "Clinical Trial Application Process - CMC:
US FDA Perspective," New Orleans, LA |
| June
2003 |
|
2003
DIA Annual Meeting, "Product Quality of Non-clinical
and Clinical Trial Materials," San Antonio, TX |
| Apr.
2003 |
|
PARCS
Meeting, "Use of SUPAC Guidances during IND Development,"
Irvine, CA |
PUBLICATIONS
(Selected Listing)
| 1. |
|
C.
Syin, D. Parzy, F. Traincard, I. Boccaccio, M.G. Joshi,
D.T. Lin, X.-M. Yang, K. Assemat, C. Doerig, and G.
Langeley, "The H89 cAMP-dependent protein kinase
inhibitor blocks Plasmodium falciparum development in
infected erythrocytes," Eur. J. Biochem. 268, 4842
(2001).
|
| |
|
|
| 2. |
|
J.P.
McDaniel, C. Syin, D.T. Lin, M.B. Joshi, S. Li, and N.D.
Goldman, "Expression and characterization of a Plasmodium
falciparum protein containing domains homologous to sarcalumenin
and a tyrosine kinase substrate, eps15," Int. J.
Parasitol. 29, 723 (1999). |
| |
|
|
| 3. |
|
M.R.
Harkness, M.L. Stephens, J.H. Lobos, W.P. Flanagan, K.M.
Carroll, R.J. May, G.L. Warner, P.R. Wilson, A.A. Bracco,
and D.T. Lin, "A comparison of aerobic PCB biodegradation
in the laboratory and in the field," Environ. Sci.
Technol. (1996). |
| |
|
|
| 4. |
|
D.T.
Lin, V.M. Powers, L.J. Reynolds, C.P. Whitman, G.L. Kenyon
and J.W. Kozarich, "Evidence for the generation of
-carboxy- -hydroxy-p-xylylene from p-(bromomethyl)mandelate
by mandelate racemase," J. Am. Chem. Soc. 110, 323
(1988). |
| |
|
|
BOOK CHAPTERS |
| 1. |
|
J.A.
Gerlt, G.L. Kenyon, J.W. Kozarich, D.T. Lin, D.C. Neidhart,
G.A. Petsko, V.M. Powers, S.C. Ransom and A.Y. Tsou, "Structure-function
relationships in mandelate racemase and muconate lactonizing
enzyme," in Chemical Aspects of Enzyme Biotechnology,
T.O. Baldwin, F.M. Raushel and A.I. Scott (eds.), Plenum,
New York, NY, 9-21 (1990). |
|
Page Updated:
April 19, 2007
|